Ocugen shares lose momentum after US$100m offering

Biopharmaceutical firm Ocugen’s shares rallied following positive clinical trial results for its Covid-19 vaccine candidate, but retreated after a share offering.

  • Ocugen Inc (Nasdaq: OCGN) share price drops to US$11.21 per share
  • Its vaccine development partner said Covaxin showed 78% overall efficacy
  • Separately, Ocugen sold US$100 million of shares to institutional investors
  • Buy and sell Ocugen shares with an IG account

Ocugen stock price hits two-month high

Shares of Ocugen - a gene therapy firm that aims to cure blindness and is also working on a new coronavirus vaccine - pulled back by 3.9% to finish Wednesday at US$11.21.

Despite the day-on-day decline, that is still the stock’s strongest close since early February 2021.

Over the past week, OCGN shares had nearly doubled from US$5.64 at last Monday’s close, thanks to encouraging results for its potential Covid-19 vaccine.

Year-to-date, the counter has shot up by over 500%, from US$1.83 at the end of 2020.

Among four analysts, three had ‘buy’ calls on OCGN shares while one recommended ‘hold’, as of Wednesday. Their average 12-month target price was US$12.50, according to Bloomberg data.

Ocugen closes US$100 million direct offering at premium

Last Friday, Ocugen said it would sell 10 million shares at US$10 apiece directly to healthcare-focused institutional investors.

The offer price was at a 7.6% premium to OCGN’s closing price of US$9.29 last Thursday.

Ocugen this Wednesday announced it has closed the offering with US$100 million in gross proceeds raised.

Net proceeds of US$93.4 million will go into general corporate purposes, capital expenditures, working capital, and general and administrative expenses.

HC Wainwright & Co acted as the exclusive placement agent. Analysts at HC Wainwright & Co gave a ‘buy’ call and US$12 target price on OCGN shares.

Positive data for Ocugen’s potential Covid-19 vaccine

Ocugen is co-developing Covid-19 vaccine candidate Covaxin with India’s Bharat Biotech, for the US market.

Last Wednesday, Ocugen said the second interim analysis of Bharat Biotech’s Phase 3 clinical trial of Covaxin yielded ‘positive’ results. The news sent OCGN shares soaring 42.9% the next day.

The product demonstrated 78% efficacy against mild, moderate, and severe Covid-19 disease, as well as 100% efficacy against severe Covid-19 disease alone.

With these ‘competitive’ results, Ocugen believes it has sufficient information to support an Emergency Use Authorization (EUA) filing in the US, noted Roth Capital analyst Zegbeh Jallah.

If EUA is granted and Covaxin can be sold in the US, ‘this could lead to a significant revenue generating opportunity for Ocugen’, Jallah added. He has a ‘buy’ call and US$10 target on OCGN.

Covaxin appears to be effective against novel mutants and has storage advantages, as it can be stored at normal refrigerator temperatures. Given this, Roth Capital maintained its ‘conviction on positive outlook on the market opportunity’.

Bruce Forrest, a member of Ocugen’s vaccine scientific advisory board, said the safety and efficacy were ‘remarkable’ considering the prevalence of several coronavirus variants circulating at the time of the trial.

The company plans to consider clinical development in special populations such as children, Forrest said.

Trade US stocks with IG today - long or short

Create an IG account or log in to your existing account to get started now.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.